Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Shah RB, Cai Q, Aron M, Berney DM, Cheville JC, Deng F-, et al. Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. Am J Cancer Res. 2021;11(8):3990-4001.

Iyengar NM, Zhou XK, Mendieta H, Giri DD, El-Hely O, Winston L, et al. Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. Cancer Prev Res (Phila). 2021;14(5):541-550.

Bortoletto P, Romanski PA, Schatz-Siemers N, Spandorfer SD. Retained products of conception as an aetiology for endometritis. BJOG. 2021.

O'Leary MK, Chen SS, Westblade LF, Alabi CA. Design of a PEGylated Antimicrobial Prodrug with Species-Specific Activation. Biomacromolecules. 2021;22(2):984-992.

Sakunrangsit N, Metheepakornchai P, Kumpunya S, Greenblatt MB, Leelahavanichkul A, Pisitkun P, et al. Etanercept prevents TNF-α mediated mandibular bone loss in FcγRIIb-/- lupus model. PLoS One. 2021;16(4):e0250215.

Ketas TJ, Chaturbhuj D, Cruz-Portillo VM, Francomano E, Golden E, Chandrasekhar S, et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. bioRxiv. 2021.

Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, et al. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Transplant Cell Ther. 2021;27(8):697.e1-697.e5.

Manning DK, Shivdasani P, Koeller DR, Schwartz A, Rana HQ, Garber JE, et al. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021;39:107653.

Kim D, Alperstein SA, Siddiqui MT. Standardizing a volume benchmark for cerebrospinal fluids for optimal diagnostic accuracy. Diagn Cytopathol. 2021;49(2):258-266.

Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828-2837.